Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nemorubicin

Drug Profile

Nemorubicin

Alternative Names: FCE 23762; Methoxymorpholinyl doxorubicin; PNU 152243; PNU-152243A

Latest Information Update: 21 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action DNA intercalators; DNA topoisomerase I inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Liver cancer; Solid tumours

Most Recent Events

  • 22 Apr 2009 Preclinical cardiotoxicity data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 09 Nov 2007 Data presented at the 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2007) added to the adverse events and Cancer therapeutic trials sections
  • 26 Apr 2007 Phase-I/II clinical trials in liver cancer in European Union (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top